Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis (Q30465168)

From Wikidata
Jump to navigation Jump to search
scientific article
edit
Language Label Description Also known as
English
Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis
scientific article

    Statements

    Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis (English)
    1 reference
    Dominique Thabut
    1 reference
    Chittaranjan Routray
    1 reference
    Uday Shergill
    1 reference
    Kevin Glaser
    1 reference
    Robert Huebert
    1 reference
    Leena Patel
    1 reference
    Tetyana Masyuk
    1 reference
    Boris Blechacz
    1 reference
    Andrew Vercnocke
    1 reference
    Erik Ritman
    1 reference
    Richard Ehman
    1 reference
    Raul Urrutia
    1 reference
    Vijay Shah
    1 reference
    26 June 2011
    1 reference
    54
    1 reference
    573-585
    1 reference

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit